Stockscreener 앱 받기
92.22
3.04%
2.72
시간 외 거래:
92.90
0.68
+0.74%
전일 마감가:
$89.50
열려 있는:
$89.99
하루 거래량:
901.38K
Relative Volume:
0.90
시가총액:
$23.32B
수익:
$3.26B
순이익/손실:
$-1.45B
주가수익비율:
-15.71
EPS:
-5.871
순현금흐름:
$1.18B
1주 성능:
+7.05%
1개월 성능:
+2.98%
6개월 성능:
+0.68%
1년 성능:
-12.15%
1일 변동 폭
$89.92
$93.15
1주일 범위
$86.14
$93.15
52주 변동 폭
$79.52
$124.00
바이오앤테크 Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
92.22 | 22.96B | 3.26B | -1.45B | 1.18B | -5.871 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
바이오앤테크 Stock (BNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-02 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-06-05 | 재확인 | H.C. Wainwright | Buy |
| 2025-05-29 | 개시 | Goldman | Neutral |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-01-10 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 재확인 | BMO Capital Markets | Outperform |
| 2024-11-19 | 개시 | Berenberg | Buy |
| 2024-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-09-24 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-08-02 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-14 | 개시 | Evercore ISI | In-line |
| 2024-02-23 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-05 | 개시 | Oppenheimer | Perform |
| 2023-12-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-10-16 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-17 | 업그레이드 | Redburn | Neutral → Buy |
| 2022-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-08-17 | 개시 | Cowen | Market Perform |
| 2022-07-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2021-12-16 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-08-11 | 업그레이드 | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-16 | 다운그레이드 | Redburn | Neutral → Sell |
| 2021-05-18 | 개시 | Goldman | Neutral |
| 2021-05-11 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-08-03 | 재개 | Berenberg | Buy |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-06-30 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 개시 | H.C. Wainwright | Neutral |
| 2020-01-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-11-05 | 개시 | Wolfe Research | Outperform |
| 2019-11-04 | 개시 | Berenberg | Buy |
| 2019-11-04 | 개시 | BofA/Merrill | Buy |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-11-04 | 개시 | JP Morgan | Overweight |
| 2019-11-04 | 개시 | SVB Leerink | Outperform |
| 2019-11-04 | 개시 | UBS | Buy |
모두보기
바이오앤테크 주식(BNTX)의 최신 뉴스
BioNTech SE Stock (US09075V1026): Buyback And Oncology Pipeline Keep Shares In Focus - AD HOC NEWS
BioNTech Trims a Quarter of Its Staff and Prepares Its First Cancer Drug for FDA Review () - aktiencheck.de
Moderna Says New COVID Vax Doesn't Infringe BioNTech IP - Law360
Comirnaty COVID-19 Vaccine: What Matters Now for US Patients - AD HOC NEWS
Bristol-Myers Upgraded, Broadcom Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech’s Pipeline Pivot Meets a Market That Won’t Look Up () - aktiencheck.de
BioNTech Stock: A Week of Crosscurrents Where Macro and a Medical Congress Collide () - aktiencheck.de
BioNTech Faces Twin Headwinds: Analyst Divergence and German Health Overhaul () - aktiencheck.de
Biontech Se Sponsored Adr Stock Price Forecast. Should You Buy BNTX? - StockInvest.us
BioNTech's Oncology Momentum Clashes With Berlin's Health-Cost Crackdown () - aktiencheck.de
BioNTech’s Costly Pivot: Cancer Pipeline Promises Meet Political and Financial Realities () - aktiencheck.de
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer - news.financial
BioNTech's ASCO Data Showcase Two Late-Stage Hopes Amid Cost Cuts and a $1 Billion Buyback - aktiencheck.de
BNTX Technical Analysis | Trend, Signals & Chart Patterns | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
BioNTech Races Toward First Oncology Approval as ASCO Data Bolsters Pipeline Credibility - aktiencheck.de
BNTX Stock Quote Price and Forecast - CNN
Pumitamig’s 72.7% Response at Reduced Dose Reshapes BioNTech’s Oncology Ambitions () - aktiencheck.de
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial - GlobeNewswire Inc.
BioNTech Juggles Vaccine Tweaks and Cancer Milestones as Investors Look Beyond COVID - aktiencheck.de
BioNTech Shows Its Hand at ASCO: A Pipeline in Full Bloom and a Radical Cost Overhaul () - aktiencheck.de
BioNTech upgraded to “buy” at UBS as next-gen cancer drugs de-risk - Investing.com
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock? - news.financial
BioNTech Grapples With Labor Strife and Analyst Skepticism as Stock Languishes () - aktiencheck.de
BioNTech’s ASCO Runway: Dual Cancer Data, a Shifting Analyst Pulse, and a Cash-Rich Pause for Growth - aktiencheck.de
BioNTech Faces Twin Test: Labor Strife Over 1,860 Jobs Meets ASCO’s Clinical Verdict () - aktiencheck.de
BioNTech Unveils $1B Buyback While Bernstein Flags Approval Risk Ahead of Oncology Data Dump - aktiencheck.de
BioNTech’s ctDNA Colorectal Cancer Study Signals Next Steps in Its Oncology Strategy - TipRanks
Bernstein initiates BioNTech stock coverage citing pipeline concerns - Investing.com
BNTX Stock Price, Quote & Chart | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
Takeover Candidates for 2026! The Life Sciences Sector Is Heating Up: Evotec, BioNxt Solutions, BioNTech, and Formycon in Focus! - news.financial
Nobel Laureate Karikó to Speak as BioNTech Cuts 1,860 Jobs in Oncology Pivot () - aktiencheck.de
BioNTech’s €500m Cost-Cutting Drive Fails to Lift Stock as Oncology Spending Soars () - aktiencheck.de
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM - Yahoo Finance
Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029? - TradingView
BioNTech authorizes $1 billion share buyback program By Investing.com - Investing.com South Africa
BioNTech authorizes $1 billion share buyback program - Investing.com
BNTX Stock News: BioNTech Announces Layoffs as Covid-19 Revenue Slides - Barchart.com
BioNTech Earnings: Clinical Development on Track, Busy Schedule for the Remainder of the Year - Morningstar
Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth - sharewise.com
BioNTech Q1 Earnings Call Highlights - Yahoo Finance
BioNTech Q1 2026 Revenue Miss Overshadows Pipeline Progress as NASDAQ:BNTX Slides - ChartMill
BioNTech earnings ahead: Can oncology offset plunging vaccine sales? - Investing.com
Mitsubishi UFJ Trust & Banking Corp Sells 92,271 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Pictet Asset Management Holding SA Buys 26,119 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech’s Cancer Pivot Faces a Defining Week as Founders Head for the Door () - aktiencheck.de
SanDisk, Western Digital, Clorox And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
BioNTech (NASDAQ:BNTX) Shares Gap DownWhat's Next? - MarketBeat
Pfizer, BioNTech Defeat Moderna COVID Jab Patent - Law360
BioNTech (BNTX) surges 6.1%: Is this an indication of further gains? - MSN
BioNTech SE Sponsored ADR $BNTX Shares Sold by Flossbach Von Storch SE - MarketBeat
Tangible book value per share of BioNTech SE Sponsored ADR – XETR:22UA - TradingView
바이오앤테크 (BNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오앤테크 주식 (BNTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Poetting Sierk | Chief Operating Officer |
Apr 22 '26 |
Sale |
110.56 |
50,000 |
5,527,960 |
399,387 |
0.94%
2.60%
자본화:
|
볼륨(24시간):